Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
462 articles with Nektar Therapeutics
-
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
-
Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. This comes only weeks after BMS abandoned its clinical collaboration program with Nektar.
-
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
4/25/2022
Nektar Therapeutics announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company's future, including its NKTR-358, NKTR-255 and several core research programs.
-
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
4/23/2022
Nektar Therapeutics announced that collaborators from the Cairo Laboratory at New York Medical College presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-tumor activities of different CAR-T therapies in a variety of cancer preclinical models.
-
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
4/22/2022
Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline.
-
Bristol Myers Squibb and Nektar Therapeutics ended their global clinical program for potential bladder cancer and renal cell carcinoma treatment.
-
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
4/14/2022
Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.
-
After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.
-
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial
3/14/2022
Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning's update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study.
-
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
3/14/2022
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial.
-
Bristol Myers Squibb and Nektar Therapeutics said their joint Phase III PIVOT IO-001 study did not meet two endpoints: progression-free survival and objective response rate.
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
2/28/2022
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets
2/17/2022
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February 28, 2022, after the close of U.S.-based financial markets.
-
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2022
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. Eastern Time.
-
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis
12/15/2021
Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored Phase 1b proof-of-concept study of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, in patients with moderate-to-severe atopic dermatitis during its Investment Community Meeting.
-
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
12/13/2021
Nektar Therapeutics (NASDAQ:NKTR) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with relapsed/refractory hematologic malignancies at the 63rd American Society of Hematology (ASH) Annual Meeting.
-
Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting
11/30/2021
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology programs: IL-2 agonist, bempegaldesleukin (BEMPEG), and IL-15 agonist, NKTR-255.
-
Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.
11/15/2021
Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Diana M. Brainard , M.D., as an independent director to its Board of Directors.
-
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/12/2021
Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
11/9/2021
Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar management on Friday, November 12, 2021, at 12:00 p.m. EST during the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.